Argentina looks to be near to finally passing its controversial patent legislation. Towards the end of July the Senate passed a corrective patent bill, which now moves to the Deputies for approval before finally becoming law.
The corrective bill establishes a transition period of five years from the date the law appears in the official bulletin. The law, passed earlier by both houses but then vetoed by President Menem (Marketletters passim), had a transition period of eight years.
National pharmaceutical companies which wish to produce drugs developed by other firms will have to pay a royalty from around the middle of the year 2000, and when agreement cannot be reached between the two parties over how much the royalty should be, a reasonable sum will be fixed based on each individual case and in line with the average rate for royalties in the industry.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze